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Estrogen hormones play an important role in controlling glu-
cose homeostasis and pancreatic -cell function. Despite the
significance of estrogen hormones for regulation of glucose
metabolism, little is known about the roles of endogenous estro-
gen metabolites in modulating pancreatic -cell function. In
this study, we evaluated the effects of major natural estrogen
metabolites, catechol estrogens, on insulin secretion in pancre-
atic -cells. We show that catechol estrogens, hydroxylated at
positions C2 and C4 of the steroid A ring, rapidly potentiated
glucose-induced insulin secretion via a nongenomic mecha-
nism. 2-Hydroxyestrone, the most abundant endogenous estro-
gen metabolite, was more efficacious in stimulating insulin
secretion than any other tested catechol estrogens. In insulin-
secreting cells, catechol estrogens produced rapid activation of
calcium influx and elevation in cytosolic free calcium. Catechol
estrogens also generated sustained elevations in cytosolic free
calciumandevoked inward ion current inHEK293 cells express-
ing the transient receptor potential A1 (TRPA1) cation channel.
Calcium influx and insulin secretion stimulated by estrogen
metabolites were dependent on the TRPA1 activity and inhib-
ited with the channel-specific pharmacological antagonists or
the siRNA. Our results suggest the role of estrogen metabolism
in a direct regulation of TRPA1 activity with potential implica-
tions for metabolic diseases.
Estrogen hormones play a critical role in the regulation of
energy homeostasis. The classical nuclear hormone estrogen
receptor and isoforms (ER andER)2 are believed tomedi-
ate the majority of the protective effects of estrogen hormones
in metabolic diseases and diabetes (1). In pancreatic -cells,
treatment with estrogens increases insulin secretion and insu-
lin biosynthesis, protects cells from an array of harmful diabe-
togenic stimuli, and stimulates -cell proliferation and regen-
eration (2–6). During pregnancy, elevation of estrogen levels
can contribute to improved islet insulin secretion and aug-
mented plasma insulin responses (7). Activation of estrogen
signaling can also be important for pancreatic-cell adaptation
to higher insulin demands at the states of insulin resistance and
hyperglycemia (8). Classical ER and ER receptors have been
described in pancreatic -cells and play somewhat different roles.
Whereas ER regulates insulin biosynthesis and improves -cell
survival, ER is involved in regulationof insulin secretionandpan-
creatic -cell numbers (4, 6).
Action of estrogens and other steroids through the classical
nuclear steroid receptors is relatively slow and requires RNA
transcription, translation, and protein synthesis. However,
rapid effects for steroid hormones were reported, and these
effects did not require changes in gene expression (9). Similar to
other steroids, estrogens can activate rapid signals, functional
within seconds or minutes, that are mediated through binding
to cell plasma membrane-associated receptors (10). The iden-
tity of receptors mediating the rapid nongenomic action of
estrogens is not fully elucidated, and multiple putative plasma
membrane estrogen binding sites were reported. Nevertheless,
one such receptor that binds estrogen, G protein–coupled
estrogen receptor 1 (GPER1), has been identified (11). In pan-
creatic -islets, activation of GPER1 protects -cells from apo-
ptosis and induces mild elevation in glucose-stimulated insulin
secretion (3, 12).
Rapid nongenomic effects of several steroids including estro-
gens involve modulation of calcium ion fluxes and ion channel
activity. Steroids were reported to alter the activity of one par-
ticular ion channel family, transient receptor potential (TRP)
channels (13). Pregnenolone sulfate and related neurosteroids
directly stimulate ion fluxes through TRPM3 channels (14, 15),
whereas progesterone inhibits TRPM3 ion currents (16).
TRPC5 channels can be activated by glucocorticoids and inhib-
ited by progesterone and dihydrotestosterone (17, 18). Estra-
diol was reported to activate TRPV5 and TRPV6 channels (19,
20). TRP channels are expressed in pancreatic -cells and can
regulate insulin secretion through modulation of membrane
depolarization and calcium influx (21).
All three major endogenous estrogens: estrone, estradiol,
and estriol, are metabolized via hydroxylation by cytochrome
P450 enzymes (22). Catechol estrogens formed by the hydrox-
ylation reaction are the major endogenous estrogen metabo-
lites (see Fig. 1A). Hydroxylation at the position C2 of the ste-
roid A ring is the prevalent metabolic pathway in the liver,
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whereas C4 hydroxylated estrogens are mostly formed in
extrahepatic tissues (23). 2-Hydroxyestrone is the most
abundant catechol estrogen, whereas 2-hydroxyestradiol
and 2-hydroxyestriol are also detected at smaller amounts
(23, 24). All 2-hydroxy catechol estrogens displayed low
affinity to the classical nuclear estrogen receptors. However,
catechol estrogen-specific membrane-binding sites that do
not display any affinity to estrogen hormones were described
(25, 26). The biological significance of catechol estrogens is
not entirely clear.
In the current study we demonstrated that endogenous
metabolites of estrogen hormones, 2- and 4-hydroxylated
catechol estrogens, can directly activate TRPA1 channels.
Activation of the TRPA1 activity with catechol estrogens in
pancreatic -cells led to elevation in cytosolic free Ca2 con-
centration ([Ca2]i) and stimulation of glucose-induced
insulin secretion. Thus, we propose a novel mechanism by
which estrogen metabolism can regulate insulin secretion
and glucose homeostasis.
Results
Catechol estrogens induce rapid stimulation of insulin
secretion in pancreatic-cells
Considering the important role of estrogen hormones in the
regulation of pancreatic -cell function and insulin secretion, we
assessed the effects of acute administration of endogenous estro-
genmetabolites, catechol estrogens (Fig. 1A), on glucose-induced
insulin secretion in isolated pancreatic islets. Insulin secretionwas
evaluated in mouse pancreatic islets in the presence of high glu-
cose concentration (17 mM) during 1 h of incubation with 10 M
steroids or the vehicle (Fig. 1B). 2-Hydroxyestradiol, 2-hydroxye-
strone, 4-hydroxyestradiol, and 4-hydroxyestrone, metabo-
lites of estradiol and estrone hydroxylated at positions 2 and
4, all significantly increased insulin secretion, whereas 2-hy-
droxyestriol, the metabolite of another estrogen hormone
estriol, did not modify insulin secretion. The most abundant
endogenous estrogen metabolite, 2-hydroxyestrone, was the
most efficacious catechol estrogen in inducing insulin secre-
tion and generated a 7-fold increase in the insulin response.
2-Methoxyestradiol, which is formed by further methylation
of 2-hydroxyestradiol, had no effect on insulin secretion.
The precursor of metabolites active in the insulin secretion
assay, estrogen hormone estradiol, did not stimulate insulin
secretion under used experimental conditions.
To rule out the involvement of the classical estrogen recep-
tors described in pancreatic -cells (ER, ER, and GPER1) in
stimulating insulin secretion with catechol estrogens, we uti-
lized selective antagonists of these receptors: ICI 182,780 and
G-15 (27, 28). Treatment of mouse pancreatic islets with either
of these two antagonists did not inhibit insulin secretion
induced with 2-hydroxyestrone (Fig. 1C). This observation, as
well as a lack of stimulation of insulin secretion with estrogen
hormone estradiol under our experimental conditions (Fig.
1A), suggests that catechol estrogens induce insulin secretion
by a novel mechanism different from activation of the known
estrogen receptors.
We selected two catechol estrogens, 2-hydroxyestrone and
2-hydroxyestradiol, which demonstrated the insulinotropic
activity in pancreatic islets, to further explore effects of this
class of compounds. Both 2-hydroxyestrone and 2-hy-
droxyestradiol produced concentration-dependent potenti-
ation of glucose-induced insulin secretion in mouse islets
(Fig. 2, A and B). 2-Hydroxyestrone displayed slightly higher
potency and efficacy in enhancing insulin secretion as com-
pared with that for 2-hydroxyestradiol. Effects of both com-
pounds on insulin secretion were also studied at different
glucose concentrations. Modulation of insulin secretion by
these steroidmetabolites was glucose concentration–depen-
dent (Fig. 2, C and D). At a basal glucose concentration of 3
mM, neither of these two compounds modulated insulin
secretion, whereas at intermediate glucose levels (9 mM),
only 2-hydroxyestrone significantly elevated insulin secre-
tion, and at high glucose levels (17 mM), both compounds
produced strong stimulation of insulin secretion.
To evaluate whether treatment of cells with catechol estro-
gens can perturb glucose-induced insulin secretion, we mea-
sured insulin secretion in response to low and high glucose
concentrations in mouse islets that were pre-exposed to 10 M
2-hydroxyestrone for 1 h and compared it with the vehicle con-
trol (Fig. 2E). Exposure of islets to 2-hydroxyestone did not
significantly disturb the subsequent islet glucose response.
Islets pretreated with 2-hydroxyestrone did not have elevated
insulin secretion at 3 mM glucose, whereas only slightly higher
insulin secretion was observed in these islets at 17 mM glucose
(Fig. 2E).
Finally, the effects of 2-hydroxyestradiol on glucose-induced
insulin secretionwere examined in human pancreatic islets iso-
lated from nondiabetic donors. 2-Hydroxyestradiol produced
up to 3-fold elevation in secreted insulin in islets from a human
nondiabetic donor (Fig. 2F). Similar stimulation of insulin
secretion with 2-hydroxyestradiol was observed in islets from
two additional human donors.
Catechol estrogens induce calcium influx and elevation of
cytosolic free Ca2 levels
To study the molecular mechanisms of catechol estrogen-
mediated potentiation of insulin secretion, we employed insu-
lin-secreting INS-1 832/13 (INS-1) cells, which display robust
responsiveness to glucose stimulation (29). Similar to isolated
islets, in INS-1 cells 2-hydroxyestrone produce strong and
concentration-dependent elevation of insulin secretion at high
glucose concentration (Fig. 3A). Elevation of [Ca2]i is a major
triggering signal for stimulation of insulin secretion.We evalu-
ated effects of 2-hydroxyestrone on [Ca2]i in INS-1 cells using
FLIPR technology (Fig. 3B). Treatment with 2-hydroxyestone
led to rapid and concentration-dependent increases in [Ca2]i.
The steroid produced elevations in [Ca2]i in INS-1 cells with
half-maximal effective concentration (EC50) of 2.1  1.2 M
(Fig. 3C). The increases in [Ca2]i induced by 2-hydroxyestone
were dependent on the presence of extracellular calcium and
were not observed in cells incubated in the calcium-free buffer
(data not shown), which suggest that the steroid raises [Ca2]i
through activation of calcium influx into the cell via a plasma
membrane–located calcium channel.
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Effects of other catechol estrogens on [Ca2]iweremeasured
at single 10 M steroid concentration. The parental hormone
estradiol and 2-hydroxyestriol did not increase [Ca2]i in INS-1
cells (Fig. 4, A and D). Other tested metabolites, 2-hydroxye-
stradiol, 2-hydroxyestrone, 4-hydroxyestradiol, and 4-hy-
droxyestrone, produced rapid elevations in [Ca2]i (Fig. 4, B,C,
E, and F). Overall, the ability of estrogenmetabolites to increase
[Ca2]i correlated well with the insulinotropic activity of these
compounds (Figs. 1B and 4G).
Activation of calcium flux and insulin secretion by catechol
estrogens depends on TRPA1 activity
Steroids are known to modulate activities of multiple
members of the TRP ion channel family. We hypothesized
that elevations in [Ca2]i with catechol estrogens can be
mediated via activation of one of the TRP channels. To test
this hypothesis, we evaluated the effects of known pharma-
cological inhibitors of TRP channels on 2-hydroxyestrone–
induced [Ca2]i increases. Of various TRP inhibitors tested
(data not shown), two compounds, A-967079 and
HC030031, specific inhibitors of TRPA1 channels (30, 31),
produced significant blockade of [Ca2]i increases generated
by 2-hydroxyestrone (Fig. 5, A and B). We used one of the
TRPA1 inhibitors, HC030031, to assess the role of TRPA1
channels in elevation of insulin secretion with catechol
estrogens. Treatment of INS-1 cells (Fig. 5C) and pancreatic
islets (Fig. 5D) with HC030031 blocked the stimulatory
effect of 2-hydroxyestrone on insulin secretion.
Figure 1. Catechol estrogens produce acute potentiationof glucose-induced insulin secretion inmousepancreatic islets.A, chemical structures of estrogen
hormone metabolites hydroxylated at positions C2 and C4 of the steroid A ring. B, effects of estradiol and hydroxylated estrogen metabolites on glucose-induced
insulin secretion in isolatedpancreatic islets.Accumulated insulin secretionduring1hof incubationwasmeasured in response to17mMglucoseand10Msteroidor
the vehicle (n 6). C, antagonists of estrogen receptors ICI 182,780 (1 M) and G-15 (10 M) did not inhibit 2-hydroxyestrone-mediated potentiation of glucose-
induced insulin secretion in isolatedpancreatic islets.Accumulated1hof insulin secretionwasmeasured in response to17mMglucose (openbars) and17mMglucose
with 10M 2-hydroxyestrone (gray bars, n 7). *, p 0.05; and ***, p 0.001 versus insulin secretion in the absence of steroid.
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Furthermore, we utilized the TRPA1-specific siRNA
probes to down-regulate expression of TRPA1 channels in
INS-1 cells and to substantiate our hypothesis that catechol
estrogens stimulate calcium influx and insulin secretion in
pancreatic -cells through activation of TRPA1 channels.
Transfection of INS-1 cells with TRPA1-specific siRNAs led
to strong decreases in TRPA1mRNA levels as determined by
quantitative RT-PCR, by 89% with siRNA1 and 60% with
siRNA2 (Fig. 6A). Neither of two used TRPA1-specific
siRNAs induce down-regulation of other TRP genes impli-
cated in regulation of insulin secretion (32), and only some
up-regulation of TRPM2 and TRPM3 mRNAs was seen with
siRNA treatments (Fig. 6A).
In INS-1 cells transfected with the control nontargeted
siRNA, the selective TRPA1 activator trans-cinnamaldehyde
(33) and 2-hydroxyestrone generated strong increases in
[Ca2]i (Fig. 6, B and C). Interestingly, these two compounds
showed differences in kinetics of calcium flux activation. If cin-
namaldehyde generated a transient increase in [Ca2]i that
faded 300 s after compound addition, 2-hydroxyestrone
induced more sustained elevation in [Ca2]i. In INS-1 cells
treated with either of the two TRPA1-specific siRNAs, [Ca2]i
responses to both cinnamaldehyde and 2-hydroxyestrone were
significantly inhibited (Fig. 6, B and C). Down-regulation of
TRPA1 expression with the specific siRNA probes blocked
[Ca2]i responses to cinnamaldehyde by 50–70% and to 2-hy-
Figure 2. 2-Hydroxyestrone (2HE1) and 2-hydroxyestradiol (2HE2) induce concentration- and glucose-dependent increases in insulin secretion
in pancreatic islets. A, effects of increasing concentrations of 2HE1 on insulin secretion in mouse islets at 17 mM glucose (n 6). B, effects of increasing
concentrations of 2HE2 on insulin secretion in mouse islets at 17 mM glucose (n  6). C, effects of 10 M 2HE1 on insulin secretion in mouse islets at
different glucose concentrations (n 6). Insulin secretion in the absence of steroid is depicted as open bars, and insulin secretion in the presence of 10
M steroid is depicted as gray bars. D, effects of 10 M 2HE2 on insulin secretion in mouse islets at different glucose concentrations (n  6). Insulin
secretion in the absence of steroid depicted as open bars and in the presence of 10 M steroid as gray bars. E, preservation of glucose-induced insulin
secretion in mouse islets pre-exposed to 2HE1. Islets were treated for the first hour of incubation with 17 mM glucose in the absence (open bars) or
presence of 10 M 2HE1 (gray bars). Then islets were washed and treated with 3 mM glucose (second hour of incubation) followed by treatment with 17
mM glucose (third hour of incubation). Insulin secretion was measured during each incubation (n 6). F, effects of 2HE2 on insulin secretion in isolated
human pancreatic islets measured in the presence of 11 mM glucose (n  6). *, p  0.05; **, p  0.01; and ***, p  0.001 versus insulin secretion in the
vehicle group at appropriate glucose concentration.
Catechol estrogens activate TRPA1
2938 J. Biol. Chem. (2019) 294(8) 2935–2946
droxyestrone by 75–80% (Fig. 6D). Knockdown of TRPA1
expression with either of two siRNA probes in INS-1 cells also
produced strong inhibition of 2-hydroxyestone induced insulin
secretion (Fig. 6E). Thus, data with TRPA1-specific siRNAs in
INS-1 cells further supported our hypothesis on the key role of
TRPA1 channels in the stimulation of calcium fluxes and insu-
lin secretion with cathechol estrogens.
Catechol estrogens induce direct activation of TRPA1 channels
To demonstrate activation of TRPA1 channels with cate-
chol estrogens, we examined [Ca2]i responses to these
compounds in HEK293 cells transfected with human TRPA1
cDNA (HEK293-TRPA1 cells). No expression of TRPA1 in the
parental HEK293 cells and specific expression of TRPA1 pro-
tein in HEK293 cells transfected with TRPA1 cDNA were con-
firmed by Western blotting (Fig. 7A). HEK293-TRPA1 cells
generated robust [Ca2]i responses to increasing concentra-
tions of 2-hydroxyestrone and 2-hydroxyestradiol (Fig. 7,B and
C). Both catechol estrogens caused sustained elevation in
[Ca2]i in HEK293-TRPA1 cells with kinetics similar to that
observed in INS-1 cells. The EC50 values for activation of
TRPA1 channels in HEK293-TRPA1 cells were 2.3  1.6 and
4.2  1.3 M for 2-hydroestrone and 2-hydroxyestradiol,
respectively (Fig. 7, D and E). In parental HEK293 cells that do
not express TRPA1, both compounds failed to induce any acti-
vation of calcium fluxes and elevations in [Ca2]i (Fig. 7,D and
E).
We next performed whole-cell patch-clamp experiments
to confirm the ability of catechol estrogens to activate
TRPA1 currents. In parental HEK293 cells, lacking the
TRPA1 protein, estradiol, 2-hydroxyestradiol, or cinnamal-
dehyde evoked no inward currents (Fig. 8A). As expected, in
HEK293 cells transfected with TRPA1 cDNA, the TRPA1
agonist cinnamaldehyde induced strong inward currents
that were inhibited with the TRPA1 antagonist A-967079
(Fig. 8B). In HEK293-TRPA1 cells, administration of 10 M
estradiol did not generate any significant currents, whereas
administration of 10 M 2-hydroxyestradiol produced
strong stimulation of ion currents (Fig. 8C). The inward cur-
rent evoked by 2-hydroxyestradiol in HEK293-TRPA1 cells
was blocked by A-967079 (Fig. 8D). To further characterize
2-hydroxyestradiol-activated TRPA1 current, we investi-
gated the current–voltage relationships (I–V) of the evoked
current. The I–V exhibited no rectification and a reversal
potential between 10 and 20 mV (Fig. 8C), which was
similar to the characteristics of the cinnamaldehyde-evoked
TRPA1 current I–V. The inward currents induced by 2-hy-
droxyestradiol and cinnamaldehyde were of similar magni-
tude, and administration of cinnamaldehyde after 2-hy-
droxyestrdaiol did not generate further significant current
increases (Fig. 8E). Together, these results show that 2-hy-
droxyestradiol is an agonist of the TRPA1 channel.
Finally, we assessed the specificity of the TRPA1 activation
with catechol estrogens by exploring effects of 2-hydroxyestra-
diol on the TRPV1 channel, a member of TRP family closely
related to TRPA1. In HEK293 cells expressing TRPV1, neither
estradiol nor 2-hydroxyestradiol stimulated ion currents,
whereas the TRPV1 agonist capsaicin generated strong inward
currents (Fig. 9,A and B), indicating that catechol estrogens are
selective TRPA1 activators.
Discussion
Estrogen hormones are important physiological regula-
tors of nutrient metabolism. In pancreatic islets, estrogens
modulate insulin synthesis, insulin secretion, -cell health,
and numbers through multiple mechanisms that involve
activation of classical nuclear ER and ER receptors and
the plasma membrane GPER1 receptor. Here we propose an
additional mechanism for estrogens to regulate insulin
secretion via production of endogenous metabolites, cate-
Figure 3. 2-Hydroxyestrone (2HE1) increases insulin secretion and
induces calcium influx in INS-1 cells.A, stimulation of insulin secretionwith
increasing concentrations of 2HE1 in INS-1 cells (n 6). **, p 0.01; and ***,
p 0.001 versus insulin secretion in the vehicle group. B, cytosolic free Ca2
responses to increasing concentrations of 2HE1 in INS-1 cells (n 3). Dotted
lines depict S.E. values. C, concentration–response curve constructed from
experiments shown in B for the average area-under-the-curve (AUC) values
for Ca2 responses to 2HE1 (n 3).
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chol estrogens, which in turn stimulate calcium influx and
insulin secretion in pancreatic -cells.
2- and 4-hydroxylated metabolites of estradiol and estrone
potently potentiated glucose-induced insulin secretion in iso-
lated pancreatic islets and insulin-secreting INS-1 cells. Stimu-
lation of insulin secretion with these catechol estrogens was
only observed at high glucose concentrations but not at basal
glucose levels. Hydroxylated estrogens produced rapid
increases in [Ca2]i through stimulation of calcium influx into
the cell. These calcium responses were blocked with selective
TRPA1 inhibitors and by down-regulation of TRPA1 expres-
sion with the specific siRNA. The selective TRPA1 inhibitor
and specific siRNAs blocked stimulation of insulin secretion
induced by catechol estrogens. Altogether, these findings sug-
gest that catechol estrogens stimulate insulin secretion in pan-
creatic -cells via activation of TRPA1 channels and induction
of calcium influx.
Furthermore, we provide direct evidence that catechol
estrogens activate TRPA1 channels and demonstrate rapid
inward current and calcium responses to these compounds
in HEK293 cells expressing TRPA1, whereas no calcium
response or ion current was observed in parental HEK293
cells and/or HEK293 cells expressing TRPV1. Notably, 2-hy-
droxyestrone evoked ion current in HEK293 cells expressing
TRPA1 in the whole-cell patch-clamp configuration, sup-
porting the direct effect of catechol estrogens on the TRPA1
channel.
Endogenousestrogenhormonesundergoextensivehydrox-
ylation at various positions of the steroid rings. Formation of
hydroxylated estrogen metabolites can occur in liver, as well
as in extrahepatic tissues (22, 23, 34). Enzymes, members of
the cytochrome P450 family responsible for the oxidative
metabolism of estrogen hormones, were well-characterized
(35). Expression of cytochromes with the highest catalytic
activities for estrogen 2-hydroxylation, CYP1A1 and 1A2
(35), was detected in both pancreatic exocrine acinar and
endocrine islet cells (36), suggesting that endogenous syn-
thesis of catechol estrogens can take place in pancreas.
Unfortunately, only scarce data exist on catechol estrogen
tissue levels. In the breast tissue, where hydroxylated estro-
Figure 4. Catechol estrogens induce increases in cytosolic free Ca2 in INS-1 cells. A–F, changes in cytosolic free Ca2 in response to 10 M of indicated
steroid in INS-1 cells (n 3).Dotted linesdepict S.E. values.G, average area-under-the-curve (AUC) values for Ca2 responses to 10M steroid constructed from
experiments shown in A–F (n 3). ***, p 0.001 versus Ca2 area under the curve in the vehicle group.
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gens were analyzed in several independent studies, catechol
estrogens accounted for majority of total tissue estrogens,
and their levels were significantly higher than levels of the
classical estrogen hormones (37, 38). In plasma, catechol
estrogen concentrations are fairly low and rarely exceed 500
pg/ml levels in premenopausal women (24, 39) because of
high clearance of hydroxylated estrogens from the blood
through further metabolism to metoxyestrogens (40). High
clearance rates and local tissue synthesis of catechol estro-
gens are consistent with the idea that effects of these com-
pounds are local and paracrine in nature.
TRPA1 is a nonselective cation channel that can conduct
Ca2 and is activated by elevated intracellular calcium.
TRPA1 is also activated by multiple noxious, dietary, and
endogenous compounds with the majority of these activa-
tors containing electrophilic carbons (41). Here, we report
another class of endogenous compounds, novel TRPA1 acti-
vators. Recent data implicate TRPA1 in the control of glu-
cose metabolism. TRPA1 agonists lower blood glucose,
increase insulin secretion, stimulate glucose uptake, inhibit
food intake, and increase secretion of intestinal incretin hor-
mones (42–45). Previous studies demonstrated that TRPA1
is expressed in pancreatic -cells and insulin-secreting cell
lines (46, 47). TPRA1 agonists invoke inward ion current,
membrane depolarization, and calcium influx in pancreatic
-cells, which leads to potentiation of glucose-dependent
insulin secretion (46). Our results are consistent with the
previously published reports on TRPA1 effects in pancreatic
-cells and confirm the role of TRPA1 in regulating insulin
secretion. Moreover, this study may implicate TRPA1 in
mediating processes of adaptation of maternal -cells to
secrete higher amounts of insulin during pregnancy.
TRPA1 is expressed in sensory neurons, and the role of
TRPA1 in mediating different types of pain is well-established
(41). Although modulation of pain with catechol estrogens was
not the topic of this study, our results may have implications in
the area of pain sensation and canprovide potential explanation
for modulation of pain sensitivity with estrogen and for differ-
ences in pain perception between men and women (48). In
summary, we provide evidence of a novel mechanism through
whichmetabolites of estrogen hormones may stimulate insulin
secretion in pancreatic -cells through direct activation of
TRPA1.
Experimental procedures
Pancreatic islet isolation and insulin secretion
Mouse pancreatic islets were isolated from male C57BL/6
mice (Envigo, Indianapolis, IN) by collagenase digestion. Use
of animals was approved by Eli Lilly and Company’s Institu-
tional Animal Care and Use Committee. Human pancreatic
islets from listed cadaver organ donors that were refused for
pancreas or islet transplantation were obtained from Prodo
Labs (Irvine, CA) and InSphero AG (Schlieren, Switzerland)
and were used in accordance with internal review board eth-
ical guidelines for use of human tissue. Islets were cultured in
RPMI 1640 medium (Invitrogen) supplemented with 11 mM
glucose, 10% (v/v) heat-inactivated fetal bovine serum (Invit-
rogen), 100 IU/ml penicillin, and 100 g/ml streptomycin
(Invitrogen). For insulin secretion studies, pancreatic islets
were starved for 30 min in Earle’s balanced salt solution
Figure 5. Pharmacological inhibitors of TRPA1 channels block 2-hydroxyestrone (2HE1) induced increases in calcium fluxes and insulin secretion. A,
cytosolic free Ca2 in INS-1 cells in response to 10M 2HE1 and in the presence of selective TRPA1 blockers, 3M A-967079 and 30MHC030031.Dotted lines
depict S.E. values.B, averagearea-under-the-curve (AUC) values for Ca2 responses constructed fromexperiments shown inA (n3). ***,p0.001 versusCa2
area under the curve in the 2HE1 group. C, effects of selective TRPA1 blocker 30 M HC030031 on insulin secretion in INS-1 cells induced with 15 mM glucose
and 10 M 2HE1. Open bars, insulin secretion without the inhibitor; gray bars, secretion with HC030031 (n  6). D, effects of selective TRPA1 blocker 30 M
HC030031 on insulin secretion in isolated mouse islets induced with 17 mM glucose and 10 M 2HE1. Open bars, insulin secretion without the inhibitor; gray
bars, secretion with HC030031 (n 6). ***, p 0.001 versus insulin secretion without the inhibitor.
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(EBSS) containing 0.1% BSA and 3 mM glucose. For static
insulin secretion studies, groups of three islets were selected
and cultured with test compounds at appropriate glucose
concentrations in 0.3 ml of EBSS for 60 min at 37 °C. All
tested compounds were obtained from Sigma–Aldrich and
Steraloids, Inc. (Newport, RI). At the end of incubation, the
supernatant was collected and submitted for insulin analysis.
Insulin levels were determined with the Meso Scale Discov-
ery (Gaithersburg, MD) electrochemiluminescence insulin
assay.
Insulinoma INS-1832/13 cell culture and insulin secretion
INS-1 832/13 cells were kindly provided by Dr. C. Newgard
(Duke University, Durham, NC). INS-1 cells were cultured in
RPMI 1640 medium supplemented with 11 mM glucose, 10%
fetal bovine serum, 10 mM HEPES, 2 mM L-glutamine, 1 mM
sodium pyruvate, and 50 M mercaptoethanol. The cells were
seeded in 96-well plates (30,000 cells/well) and cultured for 3
days. The cells were washed and then incubated in EBSS
containing 0.1% BSA and no glucose for 30 min. The starva-
tion buffer was removed, and 0.2 ml of EBSS containing 15
mM glucose and test compounds was added to cells, and
plates were incubated at 37 °C for additional 60 min. At the
end of incubation, supernatant was collected and used for
insulin analysis. The cell were lysed, and the insulin content
of the lysate was analyzed and used to normalize insulin
secretion values.
FLIPR assays in INS-1 832/13
INS-1 cells were plated in 96-well plates at 50,000 cells/well
and allowed 24 h for attachment. FLIPR Calcium 6 Assay
(Molecular Devices, San Jose, CA)was used tomonitor changes
in [Ca2]i. The cells were incubated for 30min at 37 °C in EBSS
with 0.1% BSA and then loaded with the calcium dye for 90min
at room temperature. Compounds were added to plates, and
signal was quantified by FLIPR TETRA system (Molecular
Devices).
siRNA transfection in INS-1 832/13
For siRNA studies, INS-1 were seeded into 96-well plates
at a density of 20,000 cells/well, incubated for 24 h and then
transfected with On-TargetPlus siRNAs (Dharmacon, Inc.,
Lafayette, CO) for the rat Trpa1 gene (siRNA1, catalog no.
J-100647-05; and siRNA2, catalog no. J-100647-08) or non-
Figure 6. Treatment with the TRPA1-specific siRNA blocks calcium fluxes induced by TRPA1 agonist cinnamaldehyde (CA) and 2-hydroxyestrone
(2HE1). A, mRNA expression of TRP channelmRNA in INS-1 cells treatedwith control nontargeted siRNA (black dots) and TRPA1-specific siRNA1 (blue dots) and
siRNA2 (green dots, n 6). B, cytosolic free Ca2 in response to 10 M 2HE1 in INS-1 cells treated with siRNA probes (n 3). Dotted lines depict S.E. values. C,
cytosolic free Ca2 in response to 50 M CA in INS-1 cells treated with siRNA probes (n 3). Dotted lines depict S.E. values. D, average area-under-the-curve
(AUC) values for Ca2 responses constructed from experiments shown in B and C. Black dots, nontargeted siRNA; blue dots, TRPA1 siRNA1; green dots, TRPA1
siRNA2 (n 3). E, insulin secretion in response 10M 2HE1 in INS-1 cells treatedwith nontargeted siRNA (black dots) and TRPA1-specific siRNA1 (blue dots) and
siRNA2 (green dots, n 6). *, p 0.05; and ***, p 0.001 versus signal in the nontargeted siRNA group.
Catechol estrogens activate TRPA1
2942 J. Biol. Chem. (2019) 294(8) 2935–2946
targeting On-TargetPlus Control siRNA (catalog no.
D-001810-02). The cells were transfected with 25 nM siRNA
using Lipofectamine RNAiMAX transfection reagent
(Thermo Fisher Scientific). After 24 h, the medium was
replaced with regular culture medium, and the cells were
incubated for another 72 h before calcium and insulin secre-
tion measurements were made. To measure changes in the
gene expression in transfected cells, RNA was isolated
with the SV 96 RNA isolation system (Promega, Madison,
WI). Gene expression was assessed with TaqMan real-time
PCR assays (Thermo Fisher Scientific) for the following
genes: Trpa1, Rn01473803_m1; Trpm2, Rn01429410_m1;
Trpm3, Rn01479074_m1; Trpm5, Rn01479552_m1; Trpv2,
Rn00567974_m1; Trpc1, Rn00585625_m1; and Trpc4,
Rn00696282_m1.
FLIPR assays in HEK293 cells
HEK293 cells (ATCC, Manassas, VA) were cultured in
Dulbecco’s modified Eagle’s medium/F-12 (3:1, Thermo
Fisher Scientific) supplemented with 10% fetal bovine
serum, 2 mM glutamine, 20 mM HEPES. HEK293 cells were
seeded on a 96-well plate at 15,000 cells/well, allowed 24 h
for attachment, and then transfected with 75 ng/well human
TRPA1-pcDNA3.1 plasmid using Lipofectamine LTX and
PLUS reagent (Thermo Fisher Scientific). After 24 h the
medium was replaced with regular culture medium, and the
cells were incubated for another 24 h before TRPA1 protein
and cytosolic calciummeasurements were made. For TRPA1
Western blotting protein measurements, the cells were lysed
with the radioimmune precipitation assay buffer (Sigma–
Aldrich), and equal amounts of protein samples were separated
by SDS-PAGE, transferred to the membrane, and probed with
antibodiesagainstTRPA1(NB110-40763;NovusBiologicals,Cen-
tennial, CO) and -actin (ab6276; Abcam, Cambridge, MA).
FLIPR Calcium 6 Assay (Molecular Devices) was used tomonitor
changes in [Ca2]i. The cells were incubated in Hanks’ balanced
salt solution with 0.1% BSA for 30 min and then loaded with cal-
cium dye for 90 min at 37 °C. Compounds were added to plates,
and signalwas quantifiedby theFLIPRTETRAsystem (Molecular
Devices).
Patch-clamp electrophysiology
The electrophysiological experiments were performed as
described elsewhere (49–51). Briefly, HEK cell were plated
Figure 7. Catechol estrogens stimulate Ca2 influx in HEK293-TRPA1 cells. A, Western blotting analysis of TRPA1 protein expression in HEK293 cells that
were either nontransfected or transfected with TRPA1 cDNA (HEK293-TRPA1). B, cytosolic free Ca2 responses to increasing concentrations of 2-hydroxye-
strone (2HE1) in HEK293-TRPA1 cells (n 3).Dotted lines depict S.E. values. C, cytosolic free Ca2 responses to increasing concentrations of 2-hydroxyestradiol
(2HE2) in HEK293-TRPA1 cells. Dotted lines depict S.E. values. D, concentration–response curves for average Ca2 responses to 2HE1 in HEK293-TRPA1 cells
(black circles, constructed from experiments shown in B) and in parental HEK293 cells (white circles, n 3). E, concentration–response curves for average Ca2
responses to2HE2 inHEK293-TRPA1cells (black circles, constructed fromexperiments shown inC) and innontransfectedHEK293 cells (white circles,n3).AUC,
area under the curve.
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at a low density on round 15-mm glass coverslips, and the
experiments were performed 24–48 h after transfection of
the cDNA constructs. An Axopatch 200B amplifier and Digi-
data 1550A digitizer were employed to record the currents in
voltage-clamped HEK cells using the whole-cell patch-
clamp mode. The sampling rate was set to 1 kHz. Series
resistance compensation was set to 50–70%. The cells were
voltage-clamped at a holding potential of 60 mV, and the
voltage ramps from 90 to 90 mV were applied with 2-s
intervals. The extracellular solution contained 145mMNaCl,
2.5 mM KCl, 1.2 mM CaCl2, 1 mM MgCl2, 10 mM HEPES, and
5.5 mM glucose (pH 7.2 adjusted with NaOH); the pipette
solution contained 125 mM CsMeSO3, 3.77 mM CaCl2, 2 mM
MgCl2, 10 mM EGTA (100 nM free Ca2), and 10 mM HEPES
(pH 7.2 adjusted with Trizma base). The pCLAMP 10 soft-
ware package was used for data analyses. The current densi-
ties were determined by dividing the current amplitude val-
ues by the cell capacitance. The experiments were performed
at 22–25 °C. Kruskal–Wallis one-way analysis of variance on
ranks followed by the Dunn’s all pairwise multiple compari-
son post hoc test was used to determine the significance of
changes in the tested groups.
Statistical analysis
The results are presented as the means  S.E. for the indi-
cated number of experiments. The data were analyzed with
GraphPad or SigmaPlot 13 using a four-parameter nonlinear
logistic algorithm and analysis of variance.
Figure 8.-Estradiol (E2) and 2-hydroxyestradiol (HE2) evoked inward currents in HEK293-TRPA1 cells. A, neither E2 (10M), HE2 (10M), CA (cinnam-
aldehyde (CA); 50 M), nor A-967079 (2 M) affected the background currents in HEK293-pcDNA cells. A sample trace is shown. The inset shows the current–
voltage relationships (I–V) acquired at the time points indicatedwith letters a, b, c, and d. B, cinnamaldehyde induced large inward currents in HEK-TRPA1 cells,
which were inhibited by a specific TRPA1 blocker, A-967079 (2M). The inset shows the I–V acquired at the time points indicated with letters a and b. C, E2 (10
M), HE2 (10M), and CA (50M)-induced inward currents in a HEK293-TRPA1 cell. The inset shows the I–V acquired at the time points indicated with letters a,
b, and c.D, HE2-induced currents (10M) can be inhibited by A-967079 (2M), a specific inhibitor of TRPA1. The inset shows the I–V acquired at the time points
indicated with letters a, b, and c. E, summary for the data shown in A–D. The black filled dots represent the individual data points, and the red dots and bars are
themeans S.E. (S.E.). *, p 0.05; and ***, p 0.001; ns, not significant. The horizontal bars indicate the timeswhen the tested compoundswere added to the
bath. The broken line shows the zero current level.
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